

Myanmar Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Myanmar						
2. Grant number: 1721-MMR-04c-X / 12-MMR-08b-Y						
3. Date of Decision Letter: 21 December 2017						
4. Date of the Partnership Framework Agreement: 4 April 2014						
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine						
6. Vaccine type: Pentavalent						
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID						
8. Programme duration¹: 2012 -2021						
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)						
	2012-2017	2018	2019	2020	2021	Total ²
Programme Budget (US\$)	31,912,407 ³	1,595,000	2,328,500	2,331,000	2,345,000	40,511,907
10. Vaccine introduction grant (in US\$): A VIG in the amount of US\$1,209,000 was previously disbursed on 5 November 2012.						
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴						
Type of supplies to be purchased with Gavi funds in each year	2012-2017	2018				
Number of Pentavalent vaccines doses		2,052,500				
Annual Amounts (US\$)	31,912,407 ⁵	1,595,000				
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
13. Self-procurement: Not applicable						

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1721-MMR-04c-X-C

According to the co-financing policy, Myanmar falls within the group Preparatory Transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	176,000	323,000	377,500	444,000
Number of AD syringes	130,200			
Number of safety boxes	1,450			
Value of vaccine doses (US\$)	131,952			
Total co-financing payments (US\$) (including freight)	143,000	241,500	282,000	332,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017